News

Andrew Maxwell joins BioMelbourne Network Board

The BioMelbourne network is delighted to be able to announce that Andrew Maxwell is joining our Board of Directors as of this month. As the Managing Director of Chatsworth Associates, Andrew has worked with innovators, entrepreneurs and established…

Biomedical Breakthroughs takes close look at our bodies at Melbourne Museum

If you’re reading this through the misery of a mid-winter flu, at least you’re better off than the poor Bendigo boy who found himself in World War I with a bullet wound in the arm, tuberculosis in the…

Bridge to MassChallenge open for applications

Applications are now open until September 20th, for an Australia-wide startup competition targeting the highest-impact, highest-potential entrepreneurs. The competition will bring together international judges and collaborate with Australian ecosystem leaders to identify the top startups. Finalists will receive…

Accelerating Commercialisation – Entrepreneurs’ Programme August Funding Offers

The Turnbull Government today announced that twenty businesses across Australia will be offered $11.3 million in Entrepreneurs’ Programme grants to help them break into new and international markets.A 3-D printed jaw joint replacement, termite-proof building materials and a…

Melbourne based Planet innovation tops the AFR 50 Most Innovative Companies 2016 list

Every year millions of people die or become gravely ill from infectious diseases such as influenza, HIV, Chlamydia and Zika virus. Currently, 80 per cent of all tests for infectious diseases involve taking a patient sample and sending…

Minister announces details of Biomedical Translation Fund

Innovation Minister Greg Hunt and Health Minister Sussan Ley have announced the details of the $500 million Biomedical Translation Fund (BTF), including the guidelines. In a joint statement with Health Minister Sussan Ley, Mr Hunt said the Government’s…

Big step towards cure for lifelong viral infections

New research has taken us a step closer to finding a cure for human immunodeficiency virus (HIV), as well as other infections including the glandular fever virus, which is associated with the development of lymphoma. Some infections, such…

Gordagen Receives AUD$1.3M R&D Tax Incentive

Gordagen Pharmaceuticals, a private Australian company developing biopharmaceuticals and nutraceuticals based on the medicinal properties of tocotrienols, is pleased to announce it has received a Research and Development Tax Incentive Refund of AUD$1.3 million for the 2015/2016 financial…

Fight Club – A Personal Account of Immunotherapy Treatment in Melbourne

A personal journey illustrating the potential benefits of immunotherapy and also  featuring several  leading oncology practitioners based in Melbourne When Steven Jones-Evans was diagnosed with bladder cancer, the prognosis was grim. His only hope was new – and expensive…

Stopping superbugs with a protective coat – CSIRO

Around the world 700,000 people die of drug resistant infections a year, and that figure could rise to 10 million a year by 2050. The resulting financial cost is predicted to reach $100 trillion USD. It’s a global problem…

AdAlta Ltd lists on the ASX

Melbourne-based company, and BioMelbourne Network Member,  AdAlta Limited has listed on the ASX. AdAlta is a drug discovery and development company focused on using its powerful technology platform to generate a promising new class of protein therapeutics, known…

Australian protein discovery leads to tablet that “melts away blood cancer”

A potent anti-cancer treatment co-developed and trialled in Melbourne has been granted approval for use in patients by the powerful US Food and Drug Administration (FDA). The announcement recognises that the drug, venetoclax, is a successful new therapy…

Home

News & opinion

Member Directory

Events